SP-A levels in IPF patients treated with pirfenidone or nintedanib from baseline to 3 and 6 months were found to predict progression [98], while SP-D levels in IPF patients treated with IPF predict disease progression and prognosis [99,100]. Here, SFTPA2 is linked to idiopathic pulmonary fibrosis.